PainBrake - GT Biopharma

Drug Profile

PainBrake - GT Biopharma

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Accu-Break Pharmaceuticals
  • Developer GT Biopharma
  • Class Analgesics; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 11 Sep 2017 Georgetown Translational Pharmaceuticals has been acquired and merged into GT Biopharma
  • 11 Sep 2017 GT Biopharma signs a manufacturing agreement with a New Jersey manufacturing facility for production of PainBrake tablets for Neuropathic pain
  • 11 Sep 2017 PainBrake licensed to GT Biopharma for Neuropathic pain before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top